• Symptomatic type 1 Gaucher’s disease.

Contraindicated in:

• Hypersensitivity.

Use Cautiously in:

• Lactation: Use while breastfeeding only if potential maternal benefit justifies potential risk to infant.

CV: hypotension.

Derm: pruritus, rash.

GI: abdominal discomfort, nausea.

GU: decreased urinary frequency.

Neuro: dizziness, headache.
Misc: fever, hypersensitivity reactions.

Drug-Drug:

• None reported.

• Injection: 400 units/vial;

• IV (Adults and Children): Initial range of 2.5 units/kg 3 times weekly to 15–60 units/kg every 1–2 wk. Evaluate dosage every 6 mo for possible reduction.

Cerezyme

• Prevents the accumulation of glucocerebrosides in cells. Replaces glucocerebrosidases that are deficient in type 1 Gaucher’s disease.

• Improvement in symptoms of Gaucher’s disease (anemia, thrombocytopenia, bone disease, splenomegaly, and hepatomegaly).

Therapeutic Classification: replacement enzyme

Absorption: IV administration results in complete bioavailability.

Distribution: Widely distributed.

Metabolism/Excretion: Excreted mainly by the kidneys.

Half-life: 3.6–10.4 min.

(improvement in symptoms)

• Inform patient of the purpose of this medication and the importance of treatment at least every 4 wk. Imiglucerase helps control the symptoms but does not cure Gaucher’s disease. Lifelong therapy may be required.
• Advise females of reproductive potential to notify health care professional if pregnancy is planned or suspected or if breathing. There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to imiglucerase during pregnancy. Pregnant women exposed to imiglucerase and health care providers are encouraged to contact the Gaucher patient registry at 1-800-745-4447, extension 15500 or visit www.registrynxt.com.
• Emphasize the importance of follow-up examinations and lab tests.

i-mi-GLOO-ser-ase